Filling the void: Morphological and molecular phylogenetic analyses of helminths assemblage from the Egyptian egret Bubulcus ibis.

The cattle egret (B. ibis) as a common wader birds in Egypt, they act a sole reservoir for many parasites and play a vital role in their life cycle and their distribution in their environment. The study was conducted from September 2020 to August 2021.

Probing ultrafast excited-state dynamics using EUV-IR six-wave-mixing emission spectroscopy.

Non-linear processes such as four-wave-mixing have become instrumental in attosecond EUV spectroscopy. Using EUV high harmonics in conjunction with collinear near-infrared and mid-infrared fields, we extended this approach to high-order-mixing between three colors. Specifically, we find that atomic resonances in neon exhibit a significant cross section for six-wave mixing.

Emergency oncology admissions during COVID-19 pandemic: a major institution experience from Saudi Arabia.

Background: The WHO has declared the coronavirus disease 2019 (COVID-19) pandemic in March 2020. Cancer patients are considered a highly susceptible group. The effect of this pandemic on cancer mortality is still unknown.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Purpose: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.

Patients And Methods: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents in untreated patients. Eribulin (E) has shown activity in patients who have undergone previous taxane, anthracycline, and capecitabine treatment. We aimed to evaluate the neoadjuvant use of E followed by doxorubicin and cyclophosphamide (AC) in patients with HER2-negative LABC, using as a control a randomized group of women who received weekly paclitaxel (WP).